CBD hash is surrounded by claims repeated so often that they pass for common knowledge. Some are false, some are true but badly worded, and a few are dangerous because they downplay a real risk.

This article takes the five most widespread myths and tests them against Swiss legal texts and the scientific literature. Where the standard “myth busted” answer circulating on most sites is itself inaccurate, we say so.

Important: the information provided here is general in nature and does not constitute medical advice. For any therapeutic use, consult a healthcare professional.

Key takeaways

Myth	Verdict	What matters
CBD hash is illegal in Switzerland	False	Legal below 1 % total THC, but regulated
CBD is psychoactive like THC	False, badly worded	CBD is not intoxicating, but it is psychoactive
The higher the CBD percentage, the better	False	Above 60 %, the product has been enriched
CBD hash contains no THC	False	Up to 1 %, with a real risk of a positive test
All CBD hash is the same	False	Around 70 % of tested products were mislabelled

Myth 1: “CBD hash is illegal in Switzerland”

Verdict: false, but the correct wording is more demanding than most people assume.

What Swiss law actually says

CBD hash is lawful in Switzerland as long as its total THC content stays below 1 % ^{1 2}. Two clarifications change everything.

First clarification: the threshold is not where people say it is. You will read everywhere that the 1 % limit sits in the Federal Act on Narcotics. That is inaccurate. The Narcotics Act (NarcA, SR 812.121) sets the general framework ³, but the numerical value is fixed by the FDHA Ordinance on the Lists of Narcotics (SR 812.121.11), which defines controlled cannabis as cannabis whose total THC content reaches or exceeds 1.0 % ⁴.

Second clarification: “total content” is not “THC content”. The regulatory calculation applies to total THC, meaning THC + (THCA × 0.877). A product showing 0.4 % THC and 0.9 % THCA actually carries 1.19 % total THC and falls outside the legal framework, even though the label looks reassuring. We cover this calculation in our guide to the most potent CBD hash in Switzerland.

Legal does not mean unregulated

This is the blind spot in most articles on the subject. CBD hash that complies with the THC threshold is still subject to other regimes:

• Resins intended for smoking fall under the status of tobacco substitute.
• Health claims are tightly controlled. Swissmedic publishes an enforcement aid setting the boundary between consumer product, foodstuff, cosmetic and medicine ⁵. A seller promising to treat a condition steps outside what is permitted.
• Labelling and traceability requirements apply as normal.

Legality stops at the border

The most frequently overlooked point, and the most costly in practice. CBD hash fully compliant with Swiss law becomes unlawful in most neighbouring countries, where the threshold is 0.3 % and resin is often treated separately from flower. No Swiss certificate works as a customs safe conduct.

Myth 2: “CBD is psychoactive like regular cannabis”

Verdict: false in substance, but the usual rebuttal is scientifically inaccurate.

The vocabulary problem

Almost every article answers that “CBD is not psychoactive”. The phrase is convenient but wrong in pharmacological terms. A psychoactive substance is one that acts on the central nervous system and alters mental activity. CBD does exactly that, which is precisely why it is studied for anxiety and sleep.

The accurate term is non-intoxicating. CBD produces neither euphoria, nor distorted perception, nor the characteristic THC “high”, at any dose or by any route.

This is not a terminological detail. A consumer told that a substance “does nothing to the brain” will be surprised by a sedative effect, and may wrongly conclude the product contained THC.

What the WHO concluded

The World Health Organization’s Expert Committee on Drug Dependence reviewed cannabidiol in 2018 and recommended that pure CBD not be placed under international control, finding neither abuse potential nor dependence potential ^{6 7}.

The Swiss nuance missing everywhere

Swiss CBD hash is not pure CBD. It may contain up to 1 % THC, roughly three times more than a product compliant with European Union standards. At a high dose, in a person with low tolerance, that fraction is not necessarily without perceptible effect. Claiming that CBD hash “cannot make you feel anything” is therefore imprudent.

Myth 3: “The higher the CBD percentage, the better”

Verdict: false, and the argument usually raised against it is itself questionable.

Why percentage is not a sufficient criterion

Three reasons converge.

Plant chemistry imposes a ceiling. A mechanically produced resin plateaus around 55 to 60 % total CBD. Above that, isolate or distillate has been added. The number rises, but the aromatic profile thins and the product becomes a composite.

Bioavailability decides the dose actually absorbed. One gram at 80 % contains 800 mg of CBD, which does not mean 800 mg will reach the bloodstream. The reference systematic review establishes bioavailability of around 31 % when smoked, against 5 to 19 % orally ⁸. An average product used well delivers more than a highly concentrated one used badly.

Percentage says nothing about contaminants. A resin concentrates cannabinoids, but also any pesticide residues and heavy metals present in the starting material.

The entourage effect argument deserves qualifying

The classic response to this myth invokes the entourage effect: terpenes and secondary cannabinoids supposedly act in synergy with CBD, so a balanced product would beat a heavily dosed one.

The practical conclusion is reasonable, but the justification offered is not established. The hypothesis was formulated by Ethan Russo in 2011 ⁹ and is heavily cited. Yet two recent reviews are explicit:

• A comprehensive review published in 2024 in Pharmaceuticals, conducted under PRISMA methodology, concludes that to date no reliable scientific evidence of this synergy exists, at least at the cannabinoid receptor level ¹⁰. The authors note that the poor bioavailability and short half life of most terpenes make reaching active concentrations unlikely.
• A 2023 scoping review in Biomedicines reaches the same verdict of insufficient evidence ¹¹.

A defensible formulation: choose a full profile product for its aromatic richness and low degree of processing, without attributing to it a demonstrated pharmacological amplification.

Myth 4: “CBD hash has no THC, it cannot fail a drug test”

Verdict: false, and this is the myth with the heaviest consequences.

Swiss CBD hash contains THC by design

The legal threshold is not zero, it is 1 %. A compliant Swiss CBD hash therefore contains a non-trivial amount of THC. Consuming 0.3 grams of a product at 1 % means roughly 3 mg of THC.

What the reference study shows

A controlled study published in 2020 in the Journal of Analytical Toxicology tracked participants’ urinary profiles after administration of pure CBD and of vaporized CBD-dominant cannabis, the latter containing 100 mg of CBD and 3.7 mg of THC ¹².

Results: several samples screened positive at the 20 ng/mL THC-COOH cutoff, two at the higher 50 ng/mL cutoff, and four were confirmed by LC-MS/MS at the 15 ng/mL threshold. The authors conclude that pure CBD alone does not produce a positive test under current standards, but that products also containing THC can generate confirmed positive results.

The comparison is striking: the 3.7 mg of THC in the study is the same order of magnitude as the 3 mg in a typical serving of Swiss CBD hash. The risk is not theoretical.

Behind the wheel, Switzerland applies zero tolerance

This is the point missing from nearly every article on the subject. Swiss law sets a limit of 1.5 micrograms of THC per litre of blood. Once that threshold is reached, the driver is deemed unfit to drive, without police having to establish any concrete impairment. The Federal Supreme Court has confirmed this zero tolerance approach ¹³.

The consequences are not symbolic: a custodial sentence of up to three years or a monetary penalty, alongside administrative measures affecting the licence.

Operational conclusion: do not drive after consuming CBD hash, and anticipate the risk if your job involves drug screening.

Myth 5: “All CBD hash is the same”

Verdict: false, and the available data are harsher than most people imagine.

Labelling is often inaccurate

The reference study on this question, published in JAMA in 2017, analysed 84 CBD products from 31 different companies. The result: roughly 70 % of products were mislabelled. More precisely, 42.85 % contained more CBD than stated, 26 % contained less, and only 30.95 % showed a content within 10 % of the declared value ¹⁴.

The study covered extracts sold online in the United States rather than Swiss hash, but it establishes a methodological point: without independent analytical verification, a label is merely a claim.

The production method sets the quality ceiling

Dry sifting, ice water extraction, electrostatic refining, pressing: each method has its own purity ceiling and residue profile. A product advertised at 65 % and produced by simple sieving is a technical impossibility, and therefore a warning sign.

What your senses detect, and what they do not

Sensory examination retains its usefulness:

• Texture: consistent, neither dusty nor excessively sticky.
• Aroma: vegetal and terpene rich, with no chemical or solvent note.
• Colour: uniform golden brown to green brown, without black specks of burnt material.
• Behaviour under heat: a trichome rich resin bubbles and melts, while a resin loaded with plant matter burns and blackens.

A decisive limitation: none of these criteria reveals heavy metals, pesticides or residual solvents. Contaminated hash can look and smell perfectly pleasant. Only laboratory analysis settles the question.

The verification that actually counts

Ask for a certificate of analysis and check that it includes:

1. An identified, accredited laboratory, ideally to ISO/IEC 17025.
2. A batch number matching the packaging. A generic certificate covering all production runs is worthless.
3. A recent, consistent analysis date.
4. CBD, CBDA and total CBD, plus THC, THCA and total THC.
5. Contaminant testing: pesticides, heavy metals, residual solvents, microbiology.

Further myths, more briefly

“CBD hash is a therapeutic product.” No. In Switzerland a consumer product cannot claim any curative effect without falling under therapeutic products law ⁵. Health claims on hash packaging are a regulatory warning sign.

“Natural means risk free.” No. Hemp is a bioaccumulating plant: it takes up heavy metals present in the soil. A poorly grown natural product can be more contaminated than a processed one from a controlled supply chain.

“CBD has no drug interactions.” False. CBD inhibits certain cytochrome P450 isoenzymes involved in metabolising many medicines. Medical advice is necessary if you are on treatment.

“CBD hash keeps indefinitely.” No. Terpenes are volatile and cannabinoids oxidise. Heat, light and oxygen degrade the product, with CBD slowly converting to other forms.

“Darker hash is necessarily stronger.” No. Colour depends on cultivar, oxidation and the amount of plant matter. A very dark brown can signal advanced oxidation rather than high potency.

Frequently asked questions

Is CBD hash legal everywhere in Switzerland? The 1 % total THC threshold applies at federal level. Sales remain subject to cantonal trade rules and to the sector specific regimes applying to the product concerned.

Can CBD make a saliva test positive? Roadside tests target THC, not CBD. Since Swiss CBD hash contains THC, a positive screen is possible.

How long should I wait before driving? No reliable duration can be given: kinetics depend on dose, route of administration, consumption frequency and individual metabolism. The only safe rule is not to drive after consuming.

Does a high CBD percentage compensate for poor quality? No. Percentage says nothing about purity, terpene profile or the presence of contaminants.

Is CBD addictive? The WHO assessment identified no abuse or dependence potential for pure CBD ⁶.

Can I make my own CBD hash from legal flower? Private processing raises regulatory questions distinct from simple consumption, particularly if the resulting product exceeds the total THC threshold through concentration. Processing concentrates cannabinoids, THC included.

Conclusion

The five myths examined here share one feature: the corrected version in circulation is often as approximate as the myth it claims to correct. CBD is not “non-psychoactive”, it is non-intoxicating. CBD hash is not “THC free”, it contains up to 1 %, with concrete consequences for drug screening and driving. And the entourage effect, invoked as self evident, remains a hypothesis that recent systematic reviews do not confirm.

The only robust approach is to request a certificate of analysis covering the exact batch you are buying, to read total values rather than partial ones, and to treat any health claim as a warning sign.

---

Sources

Footnotes

1. Federal Office of Public Health (FOPH). “Cannabis”. https://www.bag.admin.ch/en/addiction-and-health-cannabis ↩

2. Federal Office of Public Health (FOPH). “Cannabis”. https://www.bag.admin.ch/en/addiction-and-health-cannabis ↩

3. Swiss Confederation. Federal Act on Narcotics and Psychotropic Substances (NarcA), SR 812.121. https://www.fedlex.admin.ch/eli/cc/1952/241_241_245/en ↩

4. Swiss Confederation. FDHA Ordinance on the Lists of Narcotics, Psychotropic Substances, Precursors and Chemicals Used as Adjuvants, SR 812.121.11. https://www.fedlex.admin.ch/eli/cc/2011/363/en ↩

5. Swissmedic. “Products containing cannabidiol (CBD): overview and enforcement aid”. https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/abrenzungsfragen/produkte_mit_cannabidiolcbdueberblickundvollzugshilfe.pdf.download.pdf/produkte_mit_cannabidiolcbdueberblickundvollzugshilfe.pdf ↩ ↩²

6. World Health Organization. “Cannabidiol (CBD): Critical Review Report”, Expert Committee on Drug Dependence, 2018. https://cdn.who.int/media/docs/default-source/controlled-substances/whocbdreportmay2018-2.pdf ↩ ↩²

7. World Health Organization. “Cannabidiol (compound of cannabis)”, questions and answers. https://www.who.int/news-room/questions-and-answers/item/cannabidiol-%28compound-of-cannabis%29 ↩

8. Millar S. A., Stone N. L., Yates A. S., O’Sullivan S. E. “A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans”, Frontiers in Pharmacology, 2018, vol. 9, article 1365. https://pubmed.ncbi.nlm.nih.gov/30534073/ ↩

9. Russo E. B. “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects”, British Journal of Pharmacology, 2011, vol. 163, no. 7. https://pubmed.ncbi.nlm.nih.gov/21749363/ ↩

10. André R., Gomes A. P., Pereira-Leite C., Marques-da-Costa A., Monteiro Rodrigues L., Sassano M., Rijo P., Costa M. C. “The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review”, Pharmaceuticals, 2024, vol. 17, no. 11, article 1543. https://pubmed.ncbi.nlm.nih.gov/39598452/ ↩

11. “Decoding the Postulated Entourage Effect of Medicinal Cannabis: What It Is and What It Isn’t”, Biomedicines, 2023, vol. 11, no. 8, article 2323. https://doi.org/10.3390/biomedicines11082323 ↩

12. Spindle T. R., Cone E. J., Kuntz D., Mitchell J. M., Bigelow G. E., Flegel R., Vandrey R. “Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis”, Journal of Analytical Toxicology, 2020, vol. 44, no. 2, pp. 109 to 125. https://doi.org/10.1093/jat/bkz080 ↩

13. Swiss Federal Supreme Court, judgment 6B_282/2021. Confirmation of zero tolerance for driving under the influence of cannabis. https://www.crimen.ch/33/ ↩

14. Bonn-Miller M. O., Loflin M. J. E., Thomas B. F., Marcu J. P., Hyke T., Vandrey R. “Labeling Accuracy of Cannabidiol Extracts Sold Online”, JAMA, 2017, vol. 318, no. 17. https://pubmed.ncbi.nlm.nih.gov/29114823/ ↩